Last reviewed · How we verify

Tarceva — Competitive Intelligence Brief

Tarceva (erlotinib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Kinase Inhibitor. Area: Oncology.

marketed Kinase Inhibitor Epidermal growth factor receptor Oncology Live · refreshed every 30 min

Target snapshot

Tarceva (erlotinib) — Osi Pharms. Tarceva works by blocking the epidermal growth factor receptor, a protein that helps cancer cells grow.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Tarceva TARGET erlotinib Osi Pharms marketed Kinase Inhibitor Epidermal growth factor receptor 2004-01-01
Vizimpro dacomitinib Pfizer marketed Epidermal growth factor receptor 2018-01-01
Portrazza NECITUMUMAB Eli Lilly Co marketed Epidermal Growth Factor Receptor Antagonist [EPC] Epidermal growth factor receptor 2015-01-01
Gilotrif afatinib Boehringer Ingelheim marketed Kinase Inhibitor [EPC] Epidermal growth factor receptor 2013-01-01
Tykerb LAPATINIB Novartis marketed Kinase Inhibitor Epidermal growth factor receptor 2007-01-01
Erbitux cetuximab Imclone marketed Epidermal Growth Factor Receptor Antagonist [EPC] Epidermal growth factor receptor 2004-01-01
Iressa gefitinib Pfizer Inc. marketed Kinase Inhibitor [EPC] Epidermal growth factor receptor 2003-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Kinase Inhibitor class)

  1. Novartis · 5 drugs in this class
  2. Pfizer · 3 drugs in this class
  3. Bayer · 2 drugs in this class
  4. Boehringer Ingelheim · 2 drugs in this class
  5. Hoffmann-La Roche · 1 drug in this class
  6. Exelixis Inc · 1 drug in this class
  7. Novartis Pharm · 1 drug in this class
  8. Osi Pharms · 1 drug in this class
  9. Exelixis · 1 drug in this class
  10. Roche · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tarceva — Competitive Intelligence Brief. https://druglandscape.com/ci/erlotinib. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: